uo;Auba”) which took place in March. Funded from existing liquidity on hand, they are to be held in treasury to support Galderma’s employee participation plans, business development activities and/or treasury management. This final accelerated bookbuild offering marks the full divestment by the EQT-led consortium of investors. Emphasizing Galderma’s reliable performance and attractive outlook as a stand-alone company, it is the largest fully monetized capital gain from a single fund in the history of global private equity.

At the recent Annual General Meeting, following another record year, a dividend payment of 0.35 CHF (gross) per share was approved out of reserves from capital contributions.2

Outlook

Galderma is confirming its full-year guidance for 2026, with net sales growth of 17-20% at constant currency and a Core EBITDA margin of approximately 26% at constant currency. Based on the strong start to the year, the guidance is increas
=*=*=*=*=*=
当前为第13/27页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页